We found that low postoperative RAD50 expression was associated with reduced DFS and OS in early tumor stage (T1–2) and low-grade (G1–2) patient subgroups, supporting the potential use of RAD50 as an early prognostic biomarker in rectal cancer. This evidence concerns the gene RAD50 and rectal cancer.